Hexarelin: What the Research Shows on Its Mechanism, Benefits, and Legal Status (2026)
Hexarelin, also called examorelin, is a six-amino-acid growth-hormone-releasing peptide derived from GHRP-6. Most write-ups on hexarelin peptide benefits jump straight to muscle and recovery claims, but the published record points somewhere more specific: this is one of the most potent growth hormone releasers ever tested in people, and its most studied effect is on the heart, not the gym. Hexarelin (also called examorelin) is a synthetic hexapeptide that triggers a strong pulse of growth hormone, and separately it acts directly on cardiac tissue through a receptor that has nothing to do with growth hormone at all.
The Compound Universe Take: Hexarelin is a synthetic growth hormone secretagogue that reliably raises growth hormone in humans and shows cardioprotective effects in animals through the GHSR-1a and CD36 receptors. Human data is limited to small, mostly acute studies, and the compound was never FDA-approved, stalled in Phase II, and is a World Anti-Doping Agency banned substance sold for research use only [7].
New to this class? Start with the broader picture in growth hormone releasing peptides, then use this page for hexarelin specifically.
What is hexarelin (examorelin)?
Hexarelin is a six-amino-acid peptide (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2) derived from the earlier peptide GHRP-6 [7]. It belongs to the growth hormone secretagogue family, meaning it prompts the pituitary to release its own stored growth hormone rather than supplying growth hormone from outside.
It was developed by Mediolanum Farmaceutici and reached Phase II trials for growth hormone deficiency and congestive heart failure, but development was never completed [7]. The table below sets the baseline before the mechanism detail.
| Attribute | Detail | Evidence tier | Legal status |
|---|---|---|---|
| Compound class | Synthetic growth hormone secretagogue (hexapeptide) | Established | Not FDA-approved |
| Most studied for | GH release; cardiac function and cardioprotection | Human (GH) + Animal (cardiac) | Research use only |
| Primary receptors | GHSR-1a and CD36 | In-vitro / Animal | WADA prohibited |
| Clinical stage | Reached Phase II, development halted | Human (investigational) | Never marketed |
How hexarelin works: GHSR-1a, CD36, and growth hormone release
Hexarelin acts on two distinct receptors, and separating them is the key to reading the research honestly.
The first is GHSR-1a, the ghrelin/growth hormone secretagogue receptor. Binding here drives growth hormone release from the pituitary (Human). Hexarelin does this potently, and one rat study reported it had greater growth hormone releasing capacity than GHRH 1-29 at a matched dose [1]. In people, hexarelin raises growth hormone after intravenous, subcutaneous, intranasal, and oral dosing, which is unusual for a peptide (Human) [6].
The second receptor is CD36, a non-GHSR glycoprotein on cardiomyocytes and microvascular cells. A foundational study labeled rat cardiac membranes with a hexarelin derivative and identified the binding protein as CD36 (In-vitro / Animal) [3]. This matters because hexarelin’s cardiac effects appear to run partly through CD36, a route separate from growth hormone.
That separation is the central finding of the review literature: the cardiovascular effects of hexarelin are not reproduced by recombinant human growth hormone, and hexarelin improved cardiac function even in growth-hormone-deficient patients and hypophysectomized animals (Human pilot / Animal) [2].
Hexarelin research context: cardiac and growth hormone findings
Cardiac function and cardioprotection (mostly animal)
The largest body of hexarelin research is cardiovascular, and most of it is preclinical.
In animal models, hexarelin reduced infarct size after ischemia-reperfusion and preserved electrical properties of the heart (Animal) [2][4]. A separate study reported that it protects rat cardiomyocytes from in vivo ischemia/reperfusion injury through an interleukin-1 signaling pathway (Animal) [4].
Other rodent work found that hexarelin reduced cardiac fibrosis by lowering collagen deposition, suppressed atherosclerotic plaque formation, and improved cardiac function after experimental myocardial infarction (Animal) [2][5]. These are consistent, repeated signals, but they are signals in rats and mice.
Human cardiac and growth hormone data (limited)
Human evidence exists but is thin and mostly acute. In small studies, a single intravenous dose of hexarelin raised left ventricular ejection fraction in healthy volunteers and in bypass surgery patients within about 30 minutes, without changing heart rate or blood pressure (Human pilot) [2].
On the endocrine side, the human data is stronger. Hexarelin produces a strong growth hormone pulse in healthy adults, and one study in elderly subjects found that short-term intermittent intranasal or oral dosing did not blunt that growth hormone response (Human) [6]. Continuous dosing, by contrast, tends to partially desensitize the response, a known limit of this peptide class.
No chronic, large, controlled human trial established hexarelin as a treatment for any condition, and its Phase II program did not finish [7].
Read this before the hype: Hexarelin is not FDA-approved, was never marketed, and is sold “for research use only.” It is banned in sport by the World Anti-Doping Agency. This page summarizes published research; it is not medical advice, a dosing guide, or an endorsement of use. Legal status varies by jurisdiction and is changing.
| Effect area | Proposed mechanism | Evidence maturity | Regulatory status (US) |
|---|---|---|---|
| Growth hormone release | GHSR-1a agonism at the pituitary | Human (multiple routes) | Not FDA-approved |
| Acute inotropic effect | Raises ejection fraction, GH-independent | Human pilot (small, acute) | Investigational only |
| Cardioprotection | CD36 signaling; anti-fibrotic, anti-ischemic | Animal + in-vitro | Not FDA-approved |
| Atherosclerosis / fibrosis | Reduced collagen and plaque formation | Animal | Research use only |
Key takeaways
- Hexarelin is a potent growth hormone secretagogue, raising growth hormone in humans through GHSR-1a after oral, nasal, and injected routes [1][6].
- Its cardiac effects run partly through CD36, a receptor separate from growth hormone, which is why recombinant growth hormone does not reproduce them [2][3].
- Most cardioprotection evidence is animal, covering reduced infarct size, cardiac fibrosis, and atherosclerotic plaque, not human outcomes [2][4].
- Human data is limited to small, mostly acute studies, including short ejection-fraction rises in healthy volunteers and bypass patients [2].
- Hexarelin (examorelin) is not FDA-approved, stalled in Phase II, is WADA-prohibited, and is sold for research use only [7].
Frequently asked questions
What are the researched hexarelin peptide benefits?
In studies, hexarelin reliably raises growth hormone in humans and shows cardioprotective effects in animals, such as reduced infarct size and cardiac fibrosis. Human evidence is small and mostly short-term, so these are research findings, not proven treatments.
How does hexarelin work?
It activates the GHSR-1a receptor to trigger growth hormone release, and separately binds CD36 in heart tissue, which appears to drive cardiac effects independent of growth hormone [2][3].
Is hexarelin FDA-approved?
No. Hexarelin reached Phase II trials for growth hormone deficiency and heart failure but development stopped, and it was never approved or marketed [7].
Is hexarelin the same as examorelin?
Yes. Examorelin is the formal name for hexarelin, a synthetic hexapeptide derived from GHRP-6 [7].
Does hexarelin affect the heart directly?
Animal studies and small human pilot data suggest a direct cardiac action, including acute increases in ejection fraction, mediated partly by CD36 rather than growth hormone [2].
Is hexarelin legal?
It is not FDA-approved and is sold for research use only, and it is a banned substance in competitive sport under WADA. Legal status differs by jurisdiction and is changing, so verify current rules before relying on any claim [7].
Hexarelin, the synthetic hexapeptide also known as examorelin, sits inside the growth hormone secretagogue family alongside relatives such as GHRP-6 from which it was derived, and its dual action across the GHSR-1a ghrelin receptor and the CD36 glycoprotein is what separates its endocrine effect (growth hormone release documented in human subjects) from its cardiovascular effect (anti-fibrotic, anti-ischemic, and anti-atherosclerotic signals documented mainly in rodent hearts); Compound Universe Genome tracks each of these mechanisms against the primary literature so the profile reflects evidence maturity rather than marketing.
The honest read on hexarelin peptide benefits is a split verdict: strong, repeatable growth hormone release in humans, promising but preclinical cardioprotection in animals, and a compound that never cleared clinical development and remains research use only. Treat it as an active research subject, not a validated therapy.
Compare next: compare growth hormone peptides | GHRP-6 research summary | are peptides legal?
References
- Torsello A, et al. Mechanism of action of Hexarelin. I. Growth hormone-releasing activity in the rat. PMID 8921832.
- Mao Y, et al. The cardiovascular action of hexarelin. PMID 25278975 / PMC4178518.
- Bodart V, et al. CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. PMID 11988484.
- Huang J, et al. The Growth Hormone Secretagogue Hexarelin Protects Rat Cardiomyocytes From in vivo Ischemia/Reperfusion Injury Through Interleukin-1 Signaling Pathway. PMID 28321024.
- Tivesten A, et al. The growth hormone secretagogue hexarelin improves cardiac function in rats after experimental myocardial infarction. PMID 10614623.
- Ghigo E, et al. Short-term administration of intranasal or oral Hexarelin, a synthetic hexapeptide, does not desensitize the growth hormone responsiveness in human aging. PMID 8921821.
- Examorelin (hexarelin): synthetic GHSR agonist, reached Phase II (GH deficiency, congestive heart failure), never FDA-approved or marketed, WADA prohibited substance. Mediolanum Farmaceutici (codes EP-23905 / MF-6003).